MDxHealth SA (OTCBB: MXDH) is a multinational healthcare company that provides actionable epigenetic information to personalize the diagnosis and treatment of cancer.  The increased adoption of the company’s ConfirmMDx for Prostate Cancer testing solution within the U.S. urology community has established MDxHealth as a market leader in the important and growing field of cancer epigenetics. The company now means to leverage its expertise in epigenetics to build on the success of ConfirmMDx for Prostate Cancer and to establish MDxHealth as the molecular diagnostics leader in urological oncology. For more information, visit the company’s website at www.mdxhealth.com.